Early control treatment with montelukast in preschool children with asthma: A randomized controlled trial
| Autor: | Katsushi Miura, Kazuki Sato, Noriko Tanaka, Shigemi Yoshihara, Yusei Oshima, Tastuo Sakamoto, Akihiko Terada, Hiroyuki Mochizuki, Akiko Yamaoka, Kennichi Tokuyama, Masafumi Zaitsu, Akio Nakamura, Tetsuya Takamasu, Kunitaka Ohta, Kei Masuda, Hiroshi Tachimoto, Toshio Katsunuma, Masanori Ikeda, Hirokazu Arakawa, Mizuho Nagao, Takao Fujisawa, Yoshihiko Kitou, Norimasa Fukuda, Koichi Yamaguchi, Masao Morita, Hayao Araki, Chizu Habukawa, Naoki Shimojo, Makoto Kameda, Reiko Tokuda, Tetsuro Kitamura, Yuichi Adachi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Cyclopropanes
Male lcsh:Immunologic diseases. Allergy Pediatrics medicine.medical_specialty Population Acetates Sulfides law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Japan law medicine Clinical endpoint Immunology and Allergy Humans Cumulative incidence 030212 general & internal medicine Registries education Adrenergic beta-2 Receptor Agonists Montelukast Asthma education.field_of_study business.industry Hazard ratio Infant General Medicine medicine.disease respiratory tract diseases Clinical trial 030228 respiratory system Child Preschool Quinolines Female Drug therapy business lcsh:RC581-607 medicine.drug |
| Zdroj: | Allergology International, Vol 67, Iss 1, Pp 72-78 (2018) |
| ISSN: | 1323-8930 0000-0221 |
| Popis: | Background While Japanese guideline recommends initial control treatment for preschool children with asthma symptoms more than once a month, Western guidelines do not. To determine whether control treatment with montelukast was more effective than as-needed β 2 -agonists in this population, we conducted a randomized controlled trial. Methods Eligible patients were children aged 1–5 years who had asthma symptoms more than once a month but less than once a week. Patients were randomly assigned in a 1:1 ratio to receive montelukast 4 mg daily for 48 weeks or as-needed β 2 -agonists. The primary endpoint was the number of acute asthma exacerbations before starting step-up treatment with inhaled corticosteroids. This study is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000002219. Results From September 2009 to November 2012, 93 patients (47 in the montelukast group and 46 in the no-controller group) were enrolled into the study. All patients were included in the analysis. During the study, 13 patients (28%) in the montelukast group and 23 patients (50%) in the no-controller group had acute exacerbations with the mean numbers of 0.9 and 1.9/year, respectively ( P = 0.027). In addition, 10 (21%) and 19 (41%) patients received step-up treatment, respectively. Cumulative incidence of step-up treatment was significantly lower in the montelukast group (hazard ratio 0.45, 95% confidence interval 0.21 to 0.92; P = 0.033). Conclusions Montelukast is an effective control treatment for preschool children who had asthma symptoms more than once a month but less than once a week. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|